Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
11/2010
11/18/2010WO2010131733A1 Anti-axl antibody
11/18/2010WO2010131704A1 Test agent for visceral obesity and use thereof
11/18/2010WO2010131590A1 Diagnostic agent and therapeutic agent for tumors
11/18/2010WO2010131491A1 Method and kit for evaluation of predisposition to development of obesity, anti-obesity agent and method for screening thereof, non-human animal, adipose tissue, adipocyte, method for production of transgenic mouse, antigen, and antibody
11/18/2010WO2010131452A1 Ttk peptides and vaccines including the same
11/18/2010WO2010131235A1 Inhibitory antibody fragments to human tissue factor
11/18/2010WO2010131185A1 Blocking anti-dkk-1 antibodies and their uses
11/18/2010WO2010131115A1 Modified fluorescent proteins and methods for using same
11/18/2010WO2010130946A1 Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide
11/18/2010WO2010130832A2 Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
11/18/2010WO2010130830A2 Amino acid sequences directed against sclerostin and polypeptides comprising the same for the treatment of bone diseases and disorders
11/18/2010WO2010130824A2 Collections and uses thereof
11/18/2010WO2010130751A1 Humanized axl antibodies
11/18/2010WO2010130677A1 Vhh antibody fragments that mimic her-2/neu
11/18/2010WO2010130636A1 Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
11/18/2010WO2010108153A3 Carrier immunoglobulins and uses thereof
11/18/2010WO2010106431A3 High affinity t-cell receptor-like ny-eso-1 peptide antibodies, methods, and uses thereof
11/18/2010WO2010102792A3 Human antibodies against human fas and their use
11/18/2010WO2010100056A3 Antibodies against a proliferating inducing ligand (april)
11/18/2010WO2010080623A3 Anti-fxi antibodies and methods of use
11/18/2010WO2010056043A9 Cell-penetrating, sequence-specific and nucleic acid-hydrolyzing antibody, method for preparing the same and pharmaceutical composition comprising the same
11/18/2010WO2010039533A3 Methods for predicting production of activating signals by cross-linked binding proteins
11/18/2010WO2009146464A3 Methods and compositions for modifying levels of lignin and increasing the digestibility of cellulose by the recombinant overexpression of lignocellulolytic enzymes
11/18/2010WO2009124931A8 Single variable domains against the notch pathways
11/18/2010WO2007133816A3 Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
11/18/2010US20100293665 Plants With Increased Yield (KO NUE)
11/18/2010US20100292444 Novel Prolactin Compounds
11/18/2010US20100292443 Humanized platelet activating factor antibody design using anti-lipid antibody templates
11/18/2010US20100292442 Anti-il-17 receptor a neutralizing antibodies
11/18/2010US20100292441 Antibodies that specifically bind to GMAD
11/18/2010US20100292152 Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases
11/18/2010US20100292151 Use of human cytokine receptor
11/18/2010US20100292130 Biological active proteins having increased in vivo and/or in vitro stability
11/18/2010US20100292103 Focused libraries of genetic packages
11/18/2010US20100292095 Human monoclonal antibodies directed to sialyl lewis c, sialyl tn and n glycolylneuraminic acid epitopes and a method of analysis of stem cells comprising said epitopes
11/18/2010US20100292091 Mara family helix-turn-helix domains and their methods of use
11/18/2010US20100291709 Human nt-pro b-type natriuretic peptide assay having reduced cross-reactivity with other peptide forms
11/18/2010US20100291706 Dye conjugates and methods of use
11/18/2010US20100291677 Reducer of immunosuppression by tumor cell and antitumor agent using the same
11/18/2010US20100291676 Humanized anti-cd4 antibody with immunosuppressive properties
11/18/2010US20100291628 Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost
11/18/2010US20100291616 Novel genes, compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
11/18/2010US20100291600 Immunoassay
11/18/2010US20100291593 Method of identifying diagnostic reagents
11/18/2010US20100291590 Methods for the diagnosis and the prognosis of a brain tumor
11/18/2010US20100291579 Novel genes encoding proteins having prognostic, diagnostic, preventive, therapeutic, and other uses
11/18/2010US20100291545 Antibody having inhibitory activity on infection with hepatitis c virus (hcv) and use thereof
11/18/2010US20100291540 Carbohydrate binding module and use thereof
11/18/2010US20100291133 Recombinant protein containing a c-terminal fragment of plasmodium msp-1
11/18/2010US20100291132 Streptococcus uberis adhesion molecule
11/18/2010US20100291131 Clostridial toxin netb
11/18/2010US20100291126 Protein showing enhanced expression in cancer cells
11/18/2010US20100291125 Eta-1 gene and methods for use
11/18/2010US20100291121 Tumour-Specific Animal Proteins
11/18/2010US20100291119 Alpha B crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis
11/18/2010US20100291112 Recombinant, Single-Chain, Trivalent Tri-Specific or Bi-Specific Antibody Derivatives
11/18/2010US20100291111 Use of Anti-Alpha5Beta1 Antibodies to Inhibit Cancer Cell Proliferation
11/18/2010US20100291110 Compositions and Methods for Regulating NK Cell Activity
11/18/2010US20100291109 Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity
11/18/2010US20100291108 Antibodies to irem-1
11/18/2010US20100291106 Compositions and methods for antibodies targeting complement protein c3b
11/18/2010US20100291105 Agent for the treatment of malignant diseases
11/18/2010US20100291104 Bordetella outer-membrane protein antigens and methods of making and using the same
11/18/2010US20100291103 Polypeptides, antibody variable domains and antagonists
11/18/2010US20100291102 Therapeutic Agent
11/18/2010US20100291101 New anti-irc85 monoclonal antibody; and composition comprising the same for preventing and treating tuberculosis or enteritis disease; and the use thereof
11/18/2010US20100291100 Compositions And Methods For Screening And Using Compounds Antagonizing Spore-Surface Interactions
11/18/2010US20100291099 Novel 27411, 23413, 22438, 23553, 25278, 26212, narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, narc 25, 86604 and 32222 molecules and uses therefor
11/18/2010US20100291098 Diabetic nephropathy therapies
11/18/2010US20100291097 Monoclonal antibody
11/18/2010US20100291095 Identification of a conserved region of plasmodium falciparum msp3 targeted by biologically active antibodies
11/18/2010US20100291094 Nucleic acid encoding 238p1b2 useful in detecting cancer
11/18/2010US20100291093 Antibody-mediated disruption of quorum sensing in bacteria
11/18/2010US20100291092 Compositions and methods for detection, prevention, and treatment of anthrax and other infectious diseases
11/18/2010US20100291091 Cancer associated gene ly6k
11/18/2010US20100291088 Il-18 binding proteins
11/18/2010US20100291086 Use of estrogen and androgen binding proteins in methods and compositions for treating gynaecological cancers
11/18/2010US20100291082 Antigen presenting cell targeted anti-viral vaccines
11/18/2010US20100291081 Rage fusion proteins
11/18/2010US20100291079 Heterodimeric Follicle Stimulating Hormone-Fc (FSH-Fc) Fusion Proteins for the Treatment of Infertility
11/18/2010US20100291078 Proteinaceous binding molecules comprising purification tags or inert variable domains
11/18/2010US20100291076 Antibodies specific for dkk-1 and their uses
11/18/2010US20100291075 Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Neutralizing Antibodies
11/18/2010US20100291074 Cyclophilin d-amyloid beta interaction potentiates mitochondrial dysfunction in a transgenic mouse model of alzheimer's disease
11/18/2010US20100291073 Methods of reducing eosinophil levels
11/18/2010US20100291072 Antibody variants with faster antigen association rates
11/18/2010US20100291071 Antibody Specific Binding to A-Beta Oligomer and the Use
11/18/2010US20100291070 Type iii secretion system component protein pa1698 of pseudomonas aeruginosa
11/18/2010US20100291068 Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
11/18/2010US20100291040 Virus-like particles for treatment of viral infections
11/18/2010US20100291023 Method for extending the half-life of exogenous or endogenous soluble molecules
11/18/2010US20100291001 Metalloproteinase-binding proteins
11/18/2010US20100290993 Antibodies to IL-6 and use thereof
11/18/2010US20100290984 Anti-mrp3 antibodies and methods of use
11/18/2010CA2761891A1 Anti-axl antibody
11/18/2010CA2761800A1 Anti-human cd52 immunoglobulins
11/18/2010CA2761696A1 Blocking anti-dkk-1 antibodies and their uses
11/18/2010CA2761681A1 Neutralizing molecules to influenza viruses
11/18/2010CA2761665A1 Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide
11/18/2010CA2761648A1 Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
1 ... 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 ... 1494